Healthcare
ByAre AI Healthcare Tools Raising Ethical and Access Concerns?
January 26, 2026 | AI in Healthcare | Ethics, Equity & Policy Recent commentary in leading medical and…
Can GSK’s New Leadership Translate into Multi-Franchise Growth in 2026?
Late January 2026 | Full-Year 2025 Earnings Preview | Vaccines, Immunology & Specialty Care GlaxoSmithKline (GSK) is set…
Can Gilead Sustain Growth Beyond HIV and Hepatitis in 2026?
Late January 2026 | Full-Year 2025 Earnings Preview | Antivirals, Oncology & Emerging Therapies Gilead Sciences is set…
Is AstraZeneca Building the Most Diversified Growth Engine in Global Pharma?
Late January–Early February 2026 | Full-Year 2025 Earnings Preview | Oncology, CVRM & Platform Innovation AstraZeneca is expected…
FDA’s AZ/GSK Biologics Rejections: Data Integrity Wake-Up or R&D Overhaul Catalyst?
FDA rejection letters issued March 3-4, 2026, flagged data integrity lapses in AstraZeneca’s subcutaneous tezepelumab (asthma) and GSK’s…
Acadia’s Daybue CHMP Fight: $2B Rett Revenue at Stake or EMA Brick Wall?
Acadia Pharmaceuticals on March 3, 2026, fired back at CHMP’s rejection of Daybue (trofinetide) expansion into granular symptom…
